A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Key points
- In this article SMMT Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday.
- When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy, a result that was statistically significant, according to an abstract released Sunday ahead of a presentation at the American Society of Clinical Oncology's annual meeting.
- The Phase 3 trial was conducted in China, and a global Phase 3 study is ongoing.
- "The fact that it shows an improvement in overall survival in a difficult-to-treat patient population is very encouraging," said Dr. Suresh Ramalingam, executive director of the Winship Cancer Institute of Emory University.
- "I'm mindful...
Quick Summary
In this article SMMT Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images An experimental lung cancer drug from Akeso
Why It Matters
This development is important because it may impact public opinion, policy decisions, and future developments related to A hotly debated lung cancer drug cut the risk of death by 34.
Key Takeaways
- In this article SMMT Follow your favorite stocks CREATE FREE ACCOUNT Piotr Swat | Lightrocket | Getty Images An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday.
- When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy, a result that was statistically significant, according to an abstract released Sunday ahead of a presentation at the American Society of Clinical Oncology's annual meeting.
- The Phase 3 trial was conducted in China, and a global Phase 3 study is ongoing.
- "The fact that it shows an improvement in overall survival in a difficult-to-treat patient population is very encouraging," said Dr.
- Suresh Ramalingam, executive director of the Winship Cancer Institute of Emory University.
📌 Source: CNBC
The BriefWire